Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q1 2025 · 10-Q
Revenue$177.76M$177.76M+22.7% vs Q1 2024 Net Income$2.42M$2.42M−91.3% vs Q1 2024 EPS Diluted$0.07$0.07−90.1% vs Q1 2024 Gross Profit$97,324,000+6.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flow$55,398,000−10.6% Free Cash Flowderived$54,600,000−11.0% Margins · derivedGross margin54.8%−8.4 pt vs Q1 2024
Operating margin12.2%−21.9 pt vs Q1 2024
Net margin1.4%−17.8 pt vs Q1 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end